Involution of infantile haemangiomas after imiquimod 5% cream.
Infantile haemangioma is a common childhood condition, which usually resolves spontaneously and is managed expectantly. In a small percentage of complex cases, haemangiomas may be associated with complications such as persistent bleeding, ulceration, feeding difficulties or visual impairment. Active treatment is often necessary in such cases. Current interventions include surgical, laser and immunomodulatory treatments. Imiquimod 5% cream is a novel alternative topical treatment that may have a potential role in management of these patients. We present our experience of imiquimod 5% cream in the treatment of five children with difficult haemangiomas. We discuss its efficacy and some of the side effects that may be encountered, which have not previously been reported.
Barry
R B M
RB
Portsmouth Dermatology Centre, St Mary's Hospital, Portsmouth, Hampshire, UK. rbmbarry@hotmail.com
Hughes
B R
BR
Cook
L J
LJ
D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002675:Child, Preschool; D005260:Female; D006391:Hemangioma / Q000151:congenital / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007223:Infant; D008297:Male; D012074:Remission Induction; D012878:Skin Neoplasms / Q000151:congenital / Q000188:drug therapy*; D016896:Treatment Outcome
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod